Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race.

Abstract:

:Adoptive cellular therapy has evolved into a powerful force in the battle against cancer, holding promise for curative responses in patients with advanced and refractory tumors. Autologous T cells, reprogrammed to target malignant cells via the expression of a chimeric antigen receptor (CAR) represent the frontrunner in this approach. Tremendous clinical regressions have been achieved using CAR-T cells against a variety of cancers both in numerous preclinical studies and in several clinical trials, most notably against acute lymphoblastic leukemia, and resulted in a very recent United States Food and Drug Administration approval of the first CAR-T-cell therapy. In most studies CARs are transferred to conventional αβT cells. Nevertheless, transferring a CAR into different cell types, such as γδT cells, natural killer cells, natural killer T cells, and myeloid cells has yet received relatively little attention, although these cell types possess unique features that may aid in surmounting some of the hurdles CAR-T-cell therapy currently faces. This review focuses on CAR therapy using effectors beyond conventional αβT cells and discusses those strategies against the backdrop of developing a safe, powerful, and durable cancer therapy.

journal_name

Hum Gene Ther

journal_title

Human gene therapy

authors

Harrer DC,Dörrie J,Schaft N

doi

10.1089/hum.2017.236

subject

Has Abstract

pub_date

2018-05-01 00:00:00

pages

547-558

issue

5

eissn

1043-0342

issn

1557-7422

journal_volume

29

pub_type

杂志文章,评审
  • In vivo marking of spontaneous or vaccine-induced fibrosarcomas in the domestic house cat, using an adenoviral vector containing a bifunctional fusion protein, GAL-TEK.

    abstract::We evaluated the ability of a replication-deficient, recombinant adenoviral vector to transfer the bifunctional gene GAL-TEK, which expresses a marking/therapeutic gene product, to naturally occurring cat fibrosarcomas in situ. GAL-TEK contains an in-frame fusion of the bacterial LacZ gene for histochemical marking of...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.9-1215

    authors: Marini FC 3rd,Cannon JP,Belmont JW,Shillitoe EJ,Lapeyre JN

    更新日期:1995-09-01 00:00:00

  • Retrovirus-mediated transfer and expression of beta-hexosaminidase alpha-chain cDNA in human fibroblasts from G(M2)-gangliosidosis B1 variant.

    abstract::Mutations in the alpha-chain of lysosomal hexosaminidase (EC 3.2.1.52) underlie two distinct biochemical phenotypes known as variant B and variant B1 of G(M2) gangliosidosis. This paper shows that the transduction of human B1-type fibroblasts (producing catalytically inactive alpha-chains) with a retroviral vector enc...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303401750476267

    authors: Teixeira CA,Sena-Esteves M,Lopes L,Sá Miranda MC,Ribeiro MG

    更新日期:2001-09-20 00:00:00

  • Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate.

    abstract::The transfer of a drug resistance gene into hematopoietic cells is an approach being investigated to overcome the problem of myelosuppression produced by anticancer drugs. Chemotherapeutic agents are often given in combination in order to increase their effectiveness. Consequently, there is an advantage in designing v...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.17-2537

    authors: Beauséjour CM,Le NL,Létourneau S,Cournoyer D,Momparler RL

    更新日期:1998-11-20 00:00:00

  • Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?

    abstract::Systemic administration of currently manufactured viral stocks has not so far achieved sufficient circulating titers to allow therapeutic targeting of metastatic disease. This is due to low initial viral titers, immune inactivation, nonspecific adhesion, and loss of particles. One way to exploit the elegant molecular ...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/104303402760128504

    authors: Harrington K,Alvarez-Vallina L,Crittenden M,Gough M,Chong H,Diaz RM,Vassaux G,Lemoine N,Vile R

    更新日期:2002-07-20 00:00:00

  • Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures.

    abstract::The large amounts of recombinant adeno-associated virus (rAAV) vector needed for clinical trials and eventual commercialization require robust, economical, reproducible, and scalable production processes compatible with current good manufacturing practice. rAAV produced using baculovirus and insect cells satisfies the...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2010.250

    authors: Cecchini S,Virag T,Kotin RM

    更新日期:2011-08-01 00:00:00

  • EGTA enhancement of adenovirus-mediated gene transfer to mouse tracheal epithelium in vivo.

    abstract::Administration of recombinant adenoviral (AdV) vectors to animals can lead to inflammatory and immune responses. For therapeutic indications in which repeated treatment is necessary, such as cystic fibrosis (CF), these responses can limit the therapeutic usefulness of the vector. In principle, the utility of the vecto...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303401300042348

    authors: Chu Q,St George JA,Lukason M,Cheng SH,Scheule RK,Eastman SJ

    更新日期:2001-03-20 00:00:00

  • High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation.

    abstract::We report a novel method for targeting adenovirus-mediated gene delivery. By irradiating mammalian cells prior to adenoviral transduction, adenoviral gene transfer is greatly improved and the adenoviral genome integrates into cellular DNA. In this work, human and rodent cell lines were irradiated and subsequently tran...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.9-1025

    authors: Zeng M,Cerniglia GJ,Eck SL,Stevens CW

    更新日期:1997-06-10 00:00:00

  • Regulatable promoters for use in gene therapy applications: modification of the 5'-flanking region of the CFTR gene with multiple cAMP response elements to support basal, low-level gene expression that can be upregulated by exogenous agents that raise int

    abstract::This study focuses on the design, construction, and evaluation of a chimeric promoter for gene therapy applications where it is desirable to have low-level basal expression of the newly transferred gene, which can be induced to higher levels of expression by the administration of pharmacologic agents that can be safel...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.15-1883

    authors: Suzuki M,Singh RN,Crystal RG

    更新日期:1996-10-01 00:00:00

  • Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery.

    abstract::The recombinant adenoviral (Ad) vector is being considered as a cancer vaccine platform because it efficiently induces immune responses to tumor antigens by intradermal immunization. The aims of this study were to evaluate the potential toxicities and biodistribution after a single dose or six weekly intradermal doses...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.17.705

    authors: Plog MS,Guyre CA,Roberts BL,Goldberg M,St George JA,Perricone MA

    更新日期:2006-07-01 00:00:00

  • Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1.

    abstract::Adult T cell leukemia/lymphoma (ATL) is derived from CD4+ T cells and has a poor prognosis because of its resistance to chemotherapy. To evaluate the effectiveness of gene therapy for ATL, the effect of ganciclovir on ATL cell lines transfected with the thymidine kinase gene of herpes simplex virus type 1 (HSV-TK) was...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.18-2203

    authors: Obaru K,Fujii S,Matsushita S,Shimada T,Takatsuki K

    更新日期:1996-12-01 00:00:00

  • Regulatory and ethical issues for phase I in utero gene transfer studies.

    abstract::Clinical gene transfer research has involved adult and child subjects, and it is expected that gene transfer in fetal subjects will occur in the future. Some genetic diseases have serious adverse effects on the fetus before birth, and there is hope that prenatal gene therapy could prevent such disease progression. Res...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2011.062

    authors: Strong C

    更新日期:2011-11-01 00:00:00

  • lacZ transgenic rats tolerant for beta-galactosidase: recipients for gene transfer studies using lacZ as a reporter gene.

    abstract::Gene transfer of reporter genes may trigger immune responses against the heterologous protein resulting in shortening of gene expression and inflammation. We generated transgenic rats expressing the lacZ gene under the control of the human immunodeficiency virus type 1 (HIV-1) long-terminal repeat (LTR) (HIV-lacZ) to ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303402760128603

    authors: Ménoret S,Aubert D,Tesson L,Braudeau C,Pichard V,Ferry N,Anegon I

    更新日期:2002-07-20 00:00:00

  • The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines.

    abstract::Human serum is known to inactivate many retroviruses, including murine leukemia viruses (MLV). Exposure of vectors based on MLV to human serum components would presumably decrease the efficiency of gene transfer in vivo. Human serum also lyses xenogeneic cells, which would affect the survival of retroviral vector pack...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.5-635

    authors: Russell DW,Berger MS,Miller AD

    更新日期:1995-05-01 00:00:00

  • Cellular Therapies for Muscular Dystrophies: Frustrations and Clinical Successes.

    abstract::Cell-based therapy for muscular dystrophies was initiated in humans after promising results obtained in murine models. Early trials failed to show substantial clinical benefit, sending researchers back to the bench, which led to the discovery of many hurdles as well as many new venues to optimize this therapeutic stra...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2015.139

    authors: Negroni E,Bigot A,Butler-Browne GS,Trollet C,Mouly V

    更新日期:2016-02-01 00:00:00

  • E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.

    abstract::Gene-modified replication-competent adenoviruses (Ads) are emerging as a promising new modality for the treatment of cancer. We have previously shown that E1B 19kDa and E1B 55kDa gene-deleted Ad (Ad-DeltaE1B19/55) exhibits improved tumor-specific replication and cell lysis, leading to an enhanced antitumor effect. In ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.167

    authors: Kim J,Kim JH,Choi KJ,Kim PH,Yun CO

    更新日期:2007-09-01 00:00:00

  • Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus.

    abstract::Interleukin-12 (IL-12) is a cytokine that exhibits pleiotropic effects on lymphocytes and natural killer cells and has been shown to have promise for the immunotherapy of cancer. The combination of the immune costimulatory molecule B7.1 and IL-12 has been shown to be synergistic for T cell activation. By transfecting ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.9-1125

    authors: Anderson R,Macdonald I,Corbett T,Hacking G,Lowdell MW,Prentice HG

    更新日期:1997-06-10 00:00:00

  • Transient transfection methods for clinical adeno-associated viral vector production.

    abstract::Recombinant adeno-associated virus (AAV)-based vectors expressing therapeutic gene products have shown great potential for human gene therapy. One major challenge for translation of promising research to clinical development is the manufacture of sufficient quantities of AAV vectors that meet stringent standards for p...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2009.064

    authors: Wright JF

    更新日期:2009-07-01 00:00:00

  • Innate immunity to adenovirus.

    abstract::Human adenoviruses are the most widely used vectors in gene medicine, with applications ranging from oncolytic therapies to vaccinations, but adenovirus vectors are not without side effects. In addition, natural adenoviruses pose severe risks for immunocompromised people, yet infections are usually mild and self-limit...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2014.001

    authors: Hendrickx R,Stichling N,Koelen J,Kuryk L,Lipiec A,Greber UF

    更新日期:2014-04-01 00:00:00

  • Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation.

    abstract::Janus kinase 3 (JAK3) is an essential component of cytokine receptor signal transduction pathways required for normal lymphocyte development and function. JAK3 deficiency in both mice and humans results in severe combined immunodeficiency (SCID) and increased susceptibility to opportunistic infections. We have previou...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303400750038462

    authors: Bunting KD,Lu T,Kelly PF,Sorrentino BP

    更新日期:2000-11-20 00:00:00

  • Engineered zinc-finger proteins can compensate genetic haploinsufficiency by transcriptional activation of the wild-type allele: application to Willams-Beuren syndrome and supravalvular aortic stenosis.

    abstract::Williams-Beuren syndrome (WBS) and supravalvular aortic stenosis (SVAS) are genetic syndromes marked by the propensity to develop severe vascular stenoses. Vascular lesions in both syndromes are caused by haploinsufficiency of the elastin gene. We used these distinct genetic syndromes as models to evaluate the feasibi...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2011.201

    authors: Zhang P,Huang A,Morales-Ruiz M,Starcher BC,Huang Y,Sessa WC,Niklason LE,Giordano FJ

    更新日期:2012-11-01 00:00:00

  • FUT-175, a synthetic inhibitor of the complement pathway, protects against the inactivation of infectious retroviruses by human serum.

    abstract::Serum-induced inactivation of retroviruses is the most critical limitation for in vivo gene transfer therapy. To solve this problem, we searched for reagents that protect retroviruses from inactivation. The effects of the protease inhibitors FOY-007 and FOY-305 and of an inhibitor of the complement pathway FUT-175, al...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.13-1575

    authors: Miyao Y,Ikenaka K,Kishima H,Tamura M,Nakamura K,Kurumi M,Hayakawa T,Shimizu K

    更新日期:1997-09-01 00:00:00

  • Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells.

    abstract::An alternative form of gene therapy involves immunoisolation of a nonautologous cell line engineered to secrete a therapeutic product. Encapsulation of these cells in a biocompatible polymer serves to protect these allogeneic cells from host-versus-graft rejection while recombinant products and nutrients are able to p...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2004.15.945

    authors: Cirone P,Bourgeois JM,Shen F,Chang PL

    更新日期:2004-10-01 00:00:00

  • Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth.

    abstract::Silencing of Wnt antagonists with aberrant activation of Wnt signaling is a common phenomenon in various human cancers. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist of Wnt signaling and acts through direct binding to Wnt in the extracellular space. In this study, we tried to illuminate the impact of WIF-1 ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.005

    authors: Lin YC,You L,Xu Z,He B,Yang CT,Chen JK,Mikami I,Clément G,Shi Y,Kuchenbecker K,Okamoto J,Kashani-Sabet M,Jablons DM

    更新日期:2007-04-01 00:00:00

  • Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.

    abstract::Huntington's disease (HD) is a fatal neurodegenerative disease caused by a genetic expansion of the CAG repeat region in the huntingtin (HTT) gene. Studies in HD mouse models have shown that artificial miRNAs can reduce mutant HTT, but evidence for their effectiveness and safety in larger animals is lacking. HD transg...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2017.199

    authors: Pfister EL,DiNardo N,Mondo E,Borel F,Conroy F,Fraser C,Gernoux G,Han X,Hu D,Johnson E,Kennington L,Liu P,Reid SJ,Sapp E,Vodicka P,Kuchel T,Morton AJ,Howland D,Moser R,Sena-Esteves M,Gao G,Mueller C,DiFiglia M

    更新日期:2018-06-01 00:00:00

  • Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.

    abstract::Isolated methylmalonic acidemia (MMA), a group of autosomal recessive inborn errors of metabolism, is most commonly caused by complete (mut(0)) or partial (mut(-)) deficiency of the enzyme methylmalonyl-CoA mutase (MUT). The severe metabolic instability and increased mortality experienced by many affected individuals,...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2015.092

    authors: Harrington EA,Sloan JL,Manoli I,Chandler RJ,Schneider M,McGuire PJ,Calcedo R,Wilson JM,Venditti CP

    更新日期:2016-05-01 00:00:00

  • Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat.

    abstract::Current clinical gene therapy protocols for the treatment of human immunodeficiency virus type 1 (HIV-1) infection often involve the ex vivo transduction and expansion of CD4+ T cells derived from HIV-positive patients at a late stage in their disease (CD4 count <400). These protocols involve the transduction of T cel...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.4-487

    authors: Poznansky MC,Foxall R,Mhashilkar A,Coker R,Jones S,Ramstedt U,Marasco W

    更新日期:1998-03-01 00:00:00

  • Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice.

    abstract::With the aim of developing new gene transfer tools for treating CF with gene therapy, we have synthesized a novel family of molecules named cationic phosphonolipids. The most efficient among them were selected by in vitro screening to compare their activities in vivo in mouse lungs. We used a reporter gene whose activ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.16-2309

    authors: Guillaume-Gable C,Floch V,Mercier B,Audrézet MP,Gobin E,Le Bolch G,Yaouanc JJ,Clément JC,des Abbayes H,Leroy JP,Morin V,Férec C

    更新日期:1998-11-01 00:00:00

  • Pseudotyped adeno-associated virus 2/9-delivered CCL11 shRNA alleviates lung inflammation in an allergen-sensitized mouse model.

    abstract::Airway infiltration by eosinophils is a major characteristic of chronic asthma. CCL11 (eotaxin-1) is secreted by lung epithelial cells and functions as the major chemokine for eosinophil recruitment. Pseudotyped adeno-associated virus (AAV) 2/9, composed by the AAV2 rep and AAV9 cap genes, can efficiently target lung ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2012.012

    authors: Wu CJ,Huang WC,Chen LC,Shen CR,Kuo ML

    更新日期:2012-11-01 00:00:00

  • Hearing on the possible uses and misuses of genetic information.

    abstract::In summary, I will reiterate the five points I would like to leave with you today: First, the biological revolution has extraordinary power to do good. As long as the use of our new genetic knowledge is guided by the traditional ideals of the healing professions--to help improve the human condition without doing harm-...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1992.3.1-51

    authors: Healy B

    更新日期:1992-02-01 00:00:00

  • Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.

    abstract::Hemophilia arthropathy (HA) represents the majority of morbidity in severe hemophilia patients, especially in resource-limited countries. Adeno-associated virus (AAV)-mediated gene therapy is showing promise for managing hemophilia. However, patients with neutralizing antibodies (NAbs) against AAV, and inhibitors to c...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2019.355

    authors: Zhang F,Yan X,Li M,Hua B,Xiao X,Monahan PE,Sun J

    更新日期:2020-04-01 00:00:00